Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Roche Long Term Foundation acquired 540’000 Roche bearer shares at the price determined via an accelerated book building (ABB) process. The Foundation will use these shares to cover current as well as future obligations arising from equity compensation plans. This announcement is based on reports that a member of a shareholder group with pooled voting rights sold 2.7 million Roche bearer shares via this ABB process. Following this transaction, the shareholder group with pooled voting rights owns circa 65% (previously 67.5%) of the issued share capital of Roche.

Excerpt from:
[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares

Message from the CEO

More:
Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022

HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).

More here:
Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people...

Oslo, Norway, 10 February 2023

See original here:
Vistin Pharma ASA: Invitation to Q4 2022 conference call

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 5:00 p.m. ET.

Go here to see the original:
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference

BOSTON and LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value £0.10 per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to ten (10) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about March 10, 2023 ( the “Effective Date”).

More:
Orchard Therapeutics Announces Proposed ADS Ratio Change

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.

See the original post:
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells

Read this article:
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an...

NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors. With Dr. LaRovere’s appointment, LifeMD’s Board will comprise nine directors, seven of whom are independent.

Read the original here:
LifeMD Appoints Dr. Joan LaRovere to its Board of Directors

MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada. The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies. At any time the research results become conclusive and Sunshine Biopharma wishes to proceed to conducting a Phase I clinical trial, the Jewish General Hospital is prepared to negotiating a new agreement to define the responsibilities and obligations of the parties for such Phase I clinical trial to be performed.

Continued here:
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023.

Follow this link:
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

The Company continues to strengthen its capabilities in the North American market The Company continues to strengthen its capabilities in the North American market

Continue reading here:
Dipharma completes second phase of CGMP expansion at its Kalamazoo site

Monthly information relative to the total number of voting rights and shares composing the share capital

Visit link:
IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

Oxurion Receives Transparency Notifications

More here:
Oxurion Receives Transparency Notifications

Initiated Phase 2 proof-of-concept study of RZ402

View original post here:
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

Montrouge, France, February 10, 2023

Read more from the original source:
DBV Technologies to Participate in Upcoming Investor Conference

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS

Continued here:
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.

See the original post here:
Science 37 Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, responded today to the recent ruling by the Seoul Central District Court in favor of Medytox, Inc. related to a long-standing trade secret dispute between Medytox and Daewoong Pharmaceutical Co. Ltd. AEON stated that it does not expect the ruling will affect its ongoing clinical development or planned commercialization strategy for ABP-450 (prabotulinumtoxinA) injection in target markets.

Read the rest here:
AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong...

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10

Visit link:
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD